Skip to main content
SpringerLink
Log in

A new feature on the cholesterol-lowering landscape

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Reduction in blood levels of low-density lipoprotein cholesterol reduces the risk of coronary heart disease. The identification of a new class of compounds that upregulate the low-density lipoprotein receptor may lead to new therapeutic advances. (pages 1332–1338)

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: The regulation of cholesterol metabolism in the liver cell and the body.

References

  1. Grundy, S.M. Statin trials and goals of cholesterol-lowering therapy. Circulation 97, 1436–1439 (1998).

    Article  CAS  Google Scholar 

  2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285, 2486–2497 (2001).

  3. Grand-Perret, T. et al. SCAP ligands are potent new lipid lowering drugs. Nature Med. 7, 1332–1338 (2001).

    Article  CAS  Google Scholar 

  4. Brown, M.S. & Goldstein, J.L. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc. Natl. Acad. Sci. USA 96, 11041–11048 (1999).

    Article  CAS  Google Scholar 

  5. Edwards, P.A., Tabor, D., Kast, H.R. & Venkateswaran, A. Regulation of gene expression by SREBP and SCAP. Biochim. Biophys. Acta 1529, 103–113 (2000).

    Article  CAS  Google Scholar 

  6. Korn, B.S. et al. Blunted feedback suppression of SREBP processing by dietary cholesterol in transgenic mice expressing sterol-resistant SCAP(D443N). J. Clin. Invest. 102, 2050–2060 (1998).

    Article  CAS  Google Scholar 

  7. Sheng, Z., Otani, H., Brown, M.S. & Goldstein, J.L. Independent regulation of sterol regulatory element-binding proteins 1 and 2 in hamster liver. Proc. Natl. Acad. Sci. USA 92, 935–938 (1995).

    Article  CAS  Google Scholar 

  8. Repa, J.J. et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ. Genes Dev. 14, 2819–2830 (2000).

    Article  CAS  Google Scholar 

  9. Izzat, N.N., Deshazer, M.E. & Loose-Mitchell, D.S. New molecular targets for cholesterol-lowering therapy. J. Pharmacol. Exp. Ther. 293, 315–320 (2000).

    CAS  PubMed  Google Scholar 

  10. Bays, H.E. et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin. Ther. 23, 1209–1230 (2001).

    Article  CAS  Google Scholar 

  11. Wetterau, J.R. et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 282, 751–754 (1998).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Experimental Therapeutics University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

    Daniel J. Rader

Authors
  1. Daniel J. Rader
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rader, D. A new feature on the cholesterol-lowering landscape. Nat Med 7, 1282–1284 (2001). https://doi.org/10.1038/nm1201-1282

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm1201-1282

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation